



# **Ciclosporin Eye Drops in Ocular Graft-Versus-Host Disease: A Case Report**

**EL Filali EL Mehdi <sup>a\*</sup>, Farah Benelkadri <sup>a</sup>,  
Houssaine Ait Lhaj <sup>a</sup>, Mohamed Kriet <sup>a</sup> and Fouad EL Asri <sup>a</sup>**

<sup>a</sup> Department of Ophthalmology, Cadi Ayyad University, Med Vi University Hospital, Avicenne Military Hospital, Marrakech, Morocco.

## **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

## **Article Information**

### **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/115411>

**Case Report**

**Received: 09/02/2024**

**Accepted: 13/04/2024**

**Published: 29/04/2024**

## **ABSTRACT**

**Aims:** To report a case of severe ocular graft-versus-host disease (GVHD) managed with topical ciclosporin.

**Introduction:** Ocular graft-versus host disease is a rare and often misdiagnosed aetiology of dry eye syndrome.

**Case:** We report a case of young women presenting with a severe and bilateral ocular surface inflammation with filamentous keratitis, posterior blepharitis, Meibomian gland dysfunction and neovascular invasion. Ocular GVHD was diagnosed due to severe dry eye symptoms and a history of allogeneic haematopoietic stem cell transplantation. Immunosuppressive treatment resulted in a spectacular anatomical and clinical improvement, rapid resolution of symptoms and improvement in visual acuity.

**Conclusion:** Ocular GVHD should be considered in any severe dry eye syndrome associated with allogeneic bone marrow transplantation. Topical immunosuppressive therapies have revolutionised the curative management of these patients.

\*Corresponding author: E-mail: [dr.filali.mehdi@gmail.com](mailto:dr.filali.mehdi@gmail.com);

**Keywords:** Dry eye syndrome; ocular graft-versus-host disease; topical ciclosporin treatment; prevention.

## 1. INTRODUCTION

Ocular Graft-Versus-Host-Disease (oGVHD) remains a major cause of long-term morbidity and disability in patients who have undergone allo-haematopoietic stem cell transplantation (allo-HSCT). Often misdiagnosed as dry eye syndrome, this condition can have a significant impact on visual function and quality of life, highlighting the importance of early detection and appropriate management.


## 2. CASE PRESENTATION

We report the case of a 36-year-old female patient who presented with a three-month history of ocular redness and discomfort with foreign body sensation, which progressed rapidly without tendency to remission despite symptomatic treatment with artificial tears. Her medical history included myeloblastic leukaemia, which had been treated with a bone marrow allograft fifteen months previously. Ciclosporin 25 mg/day was her systemic treatment.


On clinical examination, visual acuity was 2/10 in the right eye and 6/10 in the left eye. Slit lamp examination revealed diffuse conjunctival hyperemia, posterior blepharitis with meibomian gland dysfunction and bilateral conjunctival palpebral fibrovascular membrane (Fig. 1).

Corneal analysis revealed a diffuse loss of corneal reflex in the right eye with predominantly inferior quasi-global filamentous keratitis, associated to an inferonasal neovascular appeal, sectorial inferotemporal limbal insufficiency and dense and diffuse superficial punctate keratitis after fluorescein staining (Fig. 2).

There was no corneal thinning or ulceration. The anterior chamber was calm and the iris was normal with no signs of uveitis. Fundus examination showed no abnormality. The Schirmer type I test was pathological (< 5 mm after 5 minutes) and the Break-up Time test was almost instantaneous. The left eye examination showed a central and inferior filamentous keratitis with dense diffuse superficial punctate keratitis.



**Fig. 1.** Image showing fibrovascular remodelling of the upper eyelids (yellow narrow). 1a/ right upper eyelid. 1b/ left upper eyelid



**Fig. 2.** Image showing filamentous keratitis of the right eye and diffuse superficial punctate keratitis after fluorescein staining

Given the bilateral nature of the dryness, the fibrovascular changes, the palpebral inflammation associated to the worsening of the symptoms despite topical symptomatic treatment, and the history of allogeneic hematological stem cell transplantation (allo-HSCT), The diagnosis of acute ocular GVH (graft-versus-host disease) was considered, and topical treatment was initiated with one month short course of corticosteroids and an immunosuppressive 2% ciclosporine eye drop, in addition to palpebral hygiene measures and artificial tears. Within three weeks after starting treatment, the patient regained 4/10 visual acuity in her right eye, the disabling symptoms had largely resolved and the local clinical signs had clearly regressed. After 3 months of treatment, the visual acuity on Snellen chart was 6/10 in the right eye and 8/10 in the left eye, and both eyes had clear corneas (Fig. 3).

### 3. DISCUSSION

Graft-versus-host disease (GVHD) is an immunological response in which the cells of the donor's immune system attack the cells of the patient receiving a haematopoietic stem cell transplant [1]. Ocular GVHD is thought to affect

between 40% and 90% of patients with chronic GVHD [1]. The main clinical manifestation of ocular GVHD is dry eye [1]. It has three components: reduced aqueous secretion by infiltrated and inflammatory lacrimal glands, reduced lipid secretion due to meibomian gland dysfunction, and reduced mucus secretion associated with the disappearance of calciform cells. More severe clinical signs may include keratoconjunctivitis sicca, bilateral marginal keratitis, corneal ulceration, limbic insufficiency, conjunctival fibrosis, symblepharon, severe blepharitis, lacrimal gland fibrosis, anterior uveitis, etc. The diagnosis of ocular GVH should be suspected in any dry syndrome in a patient who has received an allogeneic haematopoietic stem cell transplant.

The functional symptoms described by patients are aspecific: dry, red eyes, ocular irritation, foreign body sensation, photophobia, etc. ... Slit lamp examination does not reveal any pathognomonic signs, but only signs of dry syndrome of varying severity. A classification was established in 2004 by Robinson et al (Table 1) [2], and treatment obviously depends on the severity of the clinical manifestations presented by each patient.




Fig. 3. Image showing cicatrization ad-intgrum of the right and the left cornea.

Table 1. Chronic ocular GVH classification

Grade	Clinical manifestations
Grade 1	Conjunctival hyperaemia of the bulbar or palpebral conjunctiva
Grade 2	Fibrovascular remodelling of the palpebral conjunctiva covering < 25% of the total surface area of at least one eyelid
Grade 3	Fibrovascular remodelling of the palpebral conjunctiva covering 25-75% of the total surface area of at least one eyelid
Grade 4	Remodelling of >75% of the conjunctiva with or without entropion scarring of at least one eyelid

A 2006 consensus [3] and a 2013 review of the literature [4] defined four therapeutic goals: lubrication with preservative-free artificial tears, control of tear evaporation by treating meibomian gland dysfunction with lid care and, if necessary, doxycycline treatment, control of tear drainage with mechanical plugs and reduction of ocular surface inflammation. The latter is an important part of treatment. Topical corticosteroids may be used initially as a short course to reduce ocular surface inflammation, scarring and fibrosis. Cyclosporine has revolutionised the functional and visual prognosis of ocular GVHD [5]. It increases corneal sensitivity, conjunctival keratocyte density and tear function.

Malta et al. [5] even recommend a course of 0.05% cyclosporine eye drops one month prior to allogeneic transplantation in order to reduce the severity of ocular symptoms. Autologous serum, amniotic membrane grafts and scleral lenses may be an alternative in the case of a preperforation defect. It seems important to provide a framework for the management of any planned ocular surgery in a patient with a history of allogeneic stem cell transplantation [6], although there is currently no consensus on the prevention of ocular GVH [7-9]. In addition to the usual postoperative topical corticosteroids, treatment with cyclosporine ophthalmic solution 0.05% or 0.1% could limit these cases of severe ocular GVH. The methods of administering cyclosporine in these situations remains to be defined [10], and we propose that in our department, any planned surgery should be accompanied by the administration of cyclosporine eye drop in such cases, started 1 month before and continuing for at least 6 months after the surgery, in addition to standard postoperative topical corticosteroids. We also recommend extreme caution in cases of cataract surgery on pre-existing severe dryness; it is essential to check the inflammation of the ocular surface before proceeding with surgery.

#### 4. CONCLUSION

The major challenge is the early diagnosis of ocular GVH. This will allow early treatment of these patients and prevent progression to severe complications. The curative management of these patients has been revolutionised by topical immunosuppressive treatments. However, how best to prevent GVH remains to be determined.

#### CONSENT

As per international standards or university standards, patient(s) written consent has been collected and preserved by the author(s).

#### ETHICAL APPROVAL

It is not applicable.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### REFERENCES

1. Nassiri N, Eslani M, Panahi N, Mehravaran S, Ziaei A, Djalilian AR. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. *J Ophthal Vis Res.* 2013;8:351—8.
2. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. *Bone Marrow Transplant.* 2004;33:1031—5.
3. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus host disease: V. Ancillary Therapy and Supportive Care Working Group Project. *Biol Blood Marrow Transpl.* 2006;12:375—96.
4. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. *Surv Ophthalmol.* 2013;58:233—50.
5. Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A, et al. Treatment of ocular graft-versus-host-disease with topical cyclosporine 0.05 %. *Cornea.* 2010; 29:1392—6.
6. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. *Blood.* 2011;117:6714-20
7. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. *Blood.* 2009;113:5074—82

8. Townley JR, Dana R, Jacobs DS. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. *Semin Ophthalmol.* 2011; 26:251—60
9. Perez RL, Perez-Simon JA, Caballero-Velazquez T, et al. Limbus damage in ocular graft-versus-host disease. *Biol Blood Marrow Transplant.* 2011; 17:270—3
10. Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. *Blood.* 2011; 117:2275—83.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/115411>